An Open-Label, Single-Dose Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Subjects
Latest Information Update: 04 Dec 2019
At a glance
- Drugs Irsenontrine (Primary)
- Indications Lewy body disease
- Focus Pharmacokinetics
- Sponsors Eisai Inc
Most Recent Events
- 02 Dec 2019 Status changed from active, no longer recruiting to completed.
- 15 Oct 2019 Planned End Date changed from 12 Sep 2019 to 11 Oct 2019.
- 02 Sep 2019 Planned End Date changed from 26 Aug 2019 to 12 Sep 2019.